Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

(2018) Tian Zhou et al.   BIOMATERIALS

Antimicrobials: Broad-spectrum antivirals

(2018) Benson J. Edagwa et al.   NATURE MATERIALS

Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution

(2018) Bhavesh D. Kevadiya et al.   Theranostics

Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections

(2017) David Lembo et al.   Expert Opinion on Drug Delivery

Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine

(2017) Dongwei Guo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV Stigma, Retention in Care, and Adherence Among Older Black Women Living With HIV

(2017) Thurka Sangaramoorthy et al.   JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE

Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs

(2017) Divya Prakash Gnanadhas et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Long-Acting Antiretrovirals: Where Are We now?

(2017) Amesika N Nyaku et al.   Current HIV/AIDS Reports

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

(2017) Martin Markowitz et al.   Lancet HIV

Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy

(2016) Andrew Owen et al.   ADVANCED DRUG DELIVERY REVIEWS

Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity

(2016) Vivek Agrahari et al.   Nanomedicine

Development and characterization of a long-acting nanoformulated abacavir prodrug

(2016) Dhirender Singh et al.   Nanomedicine

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

(2016) Ian McGowan et al.   Lancet HIV

Purification of Nanoparticles by Size and Shape

(2016) James D. Robertson et al.   Scientific Reports

Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis

(2015) Manjula Gunawardana et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations

(2015) Pavan Puligujja et al.   BIOMATERIALS

Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations

(2015) Federica Leone et al.   Expert Opinion on Drug Delivery

Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages

(2015) Mariluz Araínga et al.   Retrovirology

Formulation and pharmacology of long-acting rilpivirine

(2015) Peter E. Williams et al.   Current Opinion in HIV and AIDS

Formulation and pharmacology of long-acting cabotegravir

(2015) Christine Trezza et al.   Current Opinion in HIV and AIDS

Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies

(2014) Benson Edagwa et al.   CURRENT MEDICINAL CHEMISTRY

Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics

(2014) Julius F. Remenar   MOLECULAR PHARMACEUTICS

Long-acting HIV drugs advanced to overcome adherence challenge

(2014) Elie Dolgin   NATURE MEDICINE

HIV-1 Latency in Monocytes/Macrophages

(2014) Amit Kumar et al.   Viruses-Basel

Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections

(2013) Pavan Puligujja et al.   Nanomedicine-Nanotechnology Biology and Medicine

Enhanced Anti-HIV Efficacy of Indinavir After Inclusion in CD4-Targeted Lipid Nanoparticles

(2012) Aaron N. Endsley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cell-mediated drug delivery

(2011) Elena V Batrakova et al.   Expert Opinion on Drug Delivery

Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives

(2010) Ranjita Shegokar et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Macrophages Recognize Size and Shape of Their Targets

(2010) Nishit Doshi et al.   PLoS One

Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage

(2010) Valentin Le Douce et al.   Retrovirology

Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS

(2009) H. Dou et al.   JOURNAL OF IMMUNOLOGY

A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages

(2008) W. Xia et al.   BLOOD

Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro

(2008) Tathagata Dutta et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES